AUROBINDO PHARMA LTD vs Max Healthcare Institute Limited

A side-by-side comparison of AUROBINDO PHARMA LTD (AUROPHARMA) and Max Healthcare Institute Limited (MAXHEALTH) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, AUROBINDO PHARMA LTD leads AUROPHARMA vs MAXHEALTH on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

25.39
P/E ratio
72.90
2.39
P/B ratio
9.82
0.26%
Dividend yield
0.18%
₹60.34
EPS
₹14.82

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

10.10%
Return on equity
14.80%
13.00%
Return on capital
15.00%
20.00%
EBITDA margin
27.00%
10.41%
Net margin
17.22%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.63%
Revenue CAGR (3Y)
22.43%
22.02%
Profit CAGR (3Y)
9.31%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹88,980 Cr
Market cap
₹1.04L Cr
₹33,653 Cr
Revenue
₹8,373 Cr
₹3,503 Cr
Net profit
₹1,442 Cr
0.21
Debt / equity
0.32
AUROBINDO PHARMA LTD
  • ["The company has delivered a poor sales growth of 6.32% over past five years.", "Company has a low return on equity of 10.8% over last 3 years.", "Company might be capitalizing the interest cost"]
Max Healthcare Institute Limited
  • ["Stock is trading at 9.78 times its book value", "Tax rate seems low", "Company has a low return on equity of 13.7% over last 3 years.", "Company might be capitalizing the interest cost", "Dividend payout has been low at 13.6% of profits over last 3 years"]
AUROBINDO PHARMA LTD full analysis Max Healthcare Institute Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.